Full text is available at the source.
Abstract
Emerging data suggest that glucagon-like peptide-1 receptor agonists and dual incretin receptor agonists may lead to oral adverse effects.
- There is a potential association between glucagon-like peptide-1 receptor agonists and oral issues such as dry mouth, altered taste, and throat discomfort.
- Alterations in salivary function could increase the risk of dental problems and oral tissue irritation.
- Metabolic and inflammatory changes from these medications may indirectly impact oral health.
- Current evidence on the oral manifestations of these treatments is limited and inconsistently reported.
- Further investigation is necessary to understand the prevalence and significance of these oral effects.
Simplified